Europe Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Filgrastim Market
Market Report Description
The Europe Filgrastim Market would witness market growth of 7.6% CAGR during the forecast period (2021-2027).
Filgrastim is basically a granulocyte colony-stimulating factor (GCSF) that helps in boosting the number of neutrophils in a patient’s blood. This medication can help in decreasing or preventing symptoms like shortness of breath, fatigue, fever, weight loss, and chills. Doctors prescribe this medication to cure different types of cancer such as lymphoma and leukemia.
The growth of the filgrastim market is attributed to the growing prevalence of numerous diseases and the increasing geriatric population. The growing pressure on the healthcare system to reduce healthcare expenditure is estimated to propel the growth of the filgrastim market. Also, the rising demand for biosimilars in curing neutropenia among the patients would bolster the growth of the filgrastim market. In addition, several companies are increasingly investing in R&D activities for the development of better and effective biosimilars, which is estimated to spur the growth of the filgrastim market in the coming years.
The rise in the number of cancer patients is creating more demand for filgrastim in the region as it is widely given to cancer patients to boost the development of white blood cells. In addition, governments across this region have framed several healthcare policies in order to provide better healthcare facilities to the people. This strong healthcare system of the region along with the supportive reimbursement policies would augment the growth of the filgrastim market.
Moreover, the increase in the population of aged people who are more prone to diseases is one of the major factors fueling the growth of the regional market. Key market players of the region are developing innovative and effective products to fulfill the increasing requirement for filgrastim in the market. Owing to this, the growth of the regional filgrastim market would witness a surge during the forecast period.
The Germany market dominated the Europe Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $65.8 million by 2027. The UK market is exhibiting a CAGR of 6.6% during (2021 - 2027). Additionally, The France market is estimated to grow at a CAGR of 8.9% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Filgrastim Market Size will Hit $953.4 million by 2027, at a CAGR of 8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Biosimilar and
- Chemotherapy induced Neutropenia
- Chronic Neutropenia and
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and
- Online Pharmacies
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free